By Kevin E. Noonan -- The Federal Circuit today denied the petitions for rehearing by the panel and rehearing by the en banc Court filed by both parties in Amgen v. Sandoz. Amgen had petitioned for rehearing on the panel's decision that the District Court correctly determined that the provisions of the BPCIA requiring disclosure to the reference product sponsor of a biosimilar applicant's application and relevant manufacturing information was optional rather than mandatory. Sandoz petitioned for rehearing on the panel's decision that the District Court had erred in deciding that the 180-day noticed of commercial marketing for the biosimilar...
↧